Compare Citius Pharmaceuticals Inc (CTXR) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Teradyne, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Teradyne, Inc. trades at $360.01 (market cap $55.30B). The key difference: Teradyne, Inc. is far larger — about 3777.3× Citius Pharmaceuticals Inc's market cap, and Teradyne, Inc. pays a 0.15% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | TER | |
|---|---|---|
Market Cap | $14.64M | $55.30B |
Sector | Health | Technology |
52-Week High | $1.82 | $483.84 |
52-Week Low | $0.53 | $90.15 |
Enterprise Value | $10.86M | $55.13B |
Dividend Yield | — | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Teradyne (TER) trades at $341.11, down 5.14% over 24 hours, with a bearish technical signal. The stock shows strong fundamentals with three consecutive quarterly earnings beats and robust profitability margins. Recent news highlights AI-driven demand boosting semiconductor testing revenue, positioning TER as a key player in robotics and AI infrastructure. Cash flow trends indicate consistent operational strength despite negative net cash flow from aggressive investing activities.
Outlook remains positive with a consensus price target of $453.60, implying 33% upside. Risks include high valuation multiples and semiconductor cycle volatility. Analyst sentiment is strongly bullish with 64.5% buy ratings, supported by expanding AI and data center markets driving long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
